Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.

Br J Cancer · 2008 · PMC2391126 · PMID 18414411

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendP =0.06so close (0.05 < p ≤ 0.1)

In addition, patients with RRM1 mRNA expression in the lowest quartile attained a significantly higher time to progression ( P =0.044) and overall survival ( P =0.02) and showed a trend towards a higher response rate ( P =0.06), compared to patients in the highest quartile of RRM1 expression.

also in 53,322 other papers

a nonsignificant trendP =0.062so close (0.05 < p ≤ 0.1)

When patients were divided by quartiles of RRM1 and RRM2 expression, the 11 patients in the lowest quartile of RRM1 expression had a longer time to progression (7.1 vs 1.7 months; P =0.04) and overall survival (10.6 vs 1.6 months; P =0.02) than the 11 patients in the highest quartile; in addition, there was a nonsignificant trend towards a higher response rate for patients in the lowest quartile, compared to those in the highest quartile (45.5 vs 20%; P =0.062) ( Table 2 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.